A hundred jobs at Pfizer’s Bothell, Washington site are on the chopping block amid the Big Pharma’s aggressive cost-cutting measures. In a statement to Fierce Pharma on Tuesday, a Pfizer spokesperson said the retrenchment effort is part of the company’s push to improve “R&D productivity and efficiency with a sharpened focus on opportunities.” The pharma is also “simplifying the way it works through digital enablement and automation, which we believe will deliver the greatest impact for patients,” the spokesperson added.
